Saturday, February 7, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Bitcoin

MicroStrategy Faces Institutional Exodus as Bitcoin Strategy Falters

Robert Sasse by Robert Sasse
November 24, 2025
in Bitcoin, Blockchain, Crypto Stocks, Tech & Software
0
Strategy Stock
0
SHARES
79
VIEWS
Share on FacebookShare on Twitter

The investment thesis behind MicroStrategy, long celebrated as a corporate Bitcoin pioneer, is facing its most severe test. Monday’s trading session witnessed substantial selling pressure on the software company’s stock, which plummeted nearly 4% at its lowest point, extending a brutal multi-week downtrend. This decline coincides with a sharp correction in Bitcoin, which has retreated from its record highs to the $83,000-$86,000 range. For a firm that has staked its entire corporate strategy on the cryptocurrency, the timing could hardly be worse, raising existential questions about its foundational business model.

The Unraveling of a Premium

At the heart of the current crisis is the dramatic implosion of MicroStrategy’s NAV premium. This metric represents the additional value investors are willing to pay for the company’s shares above the straightforward value of the Bitcoin it holds on its balance sheet. This premium has collapsed from a comfortable 2.5x in December 2024 to a meager 1.16x by late November 2025. This erosion signals a fundamental loss of market confidence in CEO Michael Saylor’s strategy of using debt and equity to accumulate Bitcoin. The financial leverage that once amplified gains during the bull market is now working decisively in reverse.

Major Investors Head for the Exits

Compounding the problem, reports from November 24 confirm that institutional heavyweights, including BlackRock, have significantly scaled back their positions in MicroStrategy. This institutional flight did not occur in a vacuum. Previously, JPMorgan divested 25% of its stake, citing official concerns over the “regulatory risks” associated with Bitcoin-heavy companies. A domino effect now appears to be in full swing, with large-scale investors withdrawing their support.

Should investors sell immediately? Or is it worth buying Strategy?

Core Holdings Under Pressure

The company’s vulnerability is directly tied to its massive Bitcoin treasury, which now holds nearly 650,000 coins. The recent price drop from a peak of $126,000 inflicts a substantial paper loss on its primary asset. While MicroStrategy demonstrated continued conviction with a purchase of 8,178 Bitcoin for $835.6 million on November 17, the overall acquisition pace has notably slowed, with only approximately 9,000 BTC added throughout the entire month. Market experts are now questioning whether the aggressive, leverage-fueled acquisition strategy is sustainable in a high-interest-rate environment without inviting dangerous margin calls.

From All-Time Highs to a Technical Breakdown

The contrast with recent performance is stark. Just one year ago, in November 2024, the stock reached an all-time high of $543 per share. Since that peak, it has surrendered approximately 60% of its value. The recent emergence of a technical “Death Cross” pattern on its charts has further confirmed the bearish trend, frightening away the last of the optimistic retail investors.

A potentially more severe threat looms on January 15, 2026. On this date, index provider MSCI will decide whether to exclude Bitcoin-concentrated companies like MicroStrategy from major stock indices. A negative decision would compel passive index funds to liquidate their holdings, dealing a potential death blow to the already beleaguered stock. In response to these mounting risks, analysts have been downgrading the stock en masse to “Hold” or “Sell” ratings and slashing their price targets. The next critical technical support level is seen at $150, a threshold that may be breached sooner than anticipated.

Ad

Strategy Stock: Buy or Sell?! New Strategy Analysis from February 7 delivers the answer:

The latest Strategy figures speak for themselves: Urgent action needed for Strategy investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from February 7.

Strategy: Buy or sell? Read more here...

Tags: Strategy
Robert Sasse

Robert Sasse

About Dr. Robert Sasse Accomplished economist, entrepreneur, and profound expert in financial markets. Dr. Robert Sasse holds a doctorate in economics and combines academic rigor with practical entrepreneurial experience. His deep expertise in economic relationships and unwavering conviction for a free-market liberal economic order drives his mission to provide investors with well-founded knowledge and guidance.
Areas of Expertise:
  • Economic Theory and Practice
  • Free-Market Economics
  • Entrepreneurship and Business Strategy
  • Investment Philosophy
Dr. Sasse's unique combination of academic knowledge and real-world business experience enables him to provide investors with comprehensive insights that bridge theory and practice.

Related Posts

OneSpan Stock
Cyber Security

OneSpan Strengthens Mobile Security Arsenal with Strategic Acquisition

February 7, 2026
Diginex Stock
Blockchain

Diginex Enters Critical Implementation Phase Following Strategic Moves

February 7, 2026
Deluxe Stock
Analysis

Deluxe Stock Gains Momentum on Successful Fintech Transition

February 6, 2026
Next Post
Intel Stock

Intel's Bold Challenge to Asian Chip Dominance

IBM Stock

IBM Stock Surges on Quantum Computing Breakthrough

Coinbase Stock

Coinbase Stock: A Strategic Offensive to Reverse Fortunes

Recommended

Super Micro Computer Stock

Super Micro Stock Surges Amid AI Infrastructure Boom

4 months ago
Adobe Stock

Adobe’s AI Ambitions Face Investor Skepticism

4 months ago
IBM Stock

Strong IBM Earnings Fail to Impress Market as Key Segment Shows Weakness

4 months ago
Inozyme Pharma Inc Stock

Inozyme Pharma Acquisition Finalized: Strategic Focus Shifts to Clinical Development

5 months ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Newsletter
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Broadcom Coca-Cola Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Newmont Mining NIO Novo Nordisk Nvidia Ocugen Opendoor Oracle Palantir PayPal Plug Power QuantumScape Robinhood Rocket Lab USA Strategy Super Micro Computer Synopsys Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics
No Result
View All Result

Highlights

Myers Industries Set to Report Full-Year and Q4 2025 Results

OneSpan Strengthens Mobile Security Arsenal with Strategic Acquisition

Riley Exploration Permian Bolsters Board with Industry Veteran Amid Shareholder Activity

Great Lakes Dredge & Dock: A Cash Flow Inflection Point Approaches

Investors Await March Report for Boston Omaha’s Strategic Direction

Universal Insurance Maintains Quarterly Payout Amid Sector Headwinds

Trending

Orthofix Medical Stock
Earnings

Orthofix Medical Strengthens Scientific Foundation for Biologics Portfolio

by Rodolfo Hanigan
February 7, 2026
0

Investor attention turns to Orthofix Medical as the company bolsters the clinical support for its biologics business...

CrossFirst Bankshares Stock

A New Chapter for First Busey as CrossFirst Merger Finalizes

February 7, 2026
Golden Entertainment Stock

Golden Entertainment to Exit Public Markets in Strategic Privatization Deal

February 7, 2026
Myers Industries Stock

Myers Industries Set to Report Full-Year and Q4 2025 Results

February 7, 2026
OneSpan Stock

OneSpan Strengthens Mobile Security Arsenal with Strategic Acquisition

February 7, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Orthofix Medical Strengthens Scientific Foundation for Biologics Portfolio
  • A New Chapter for First Busey as CrossFirst Merger Finalizes
  • Golden Entertainment to Exit Public Markets in Strategic Privatization Deal

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com